Results 41 to 50 of about 8,230,812 (271)

Patient safety : Cardio and cerebrovascular risk of major adverse events following exposure to potentially inappropriate medications

, 2022
Chapter 1 introduces what is known about the current challenges of medication management in the elderly, with a special focus on management of potentially inappropriate medications (PIMs) in clinical practice.
Aguiar, João Pedro
core   +1 more source

Prediction of 2-Year Major Adverse Limb Event-Free Survival After Percutaneous Transluminal Angioplasty and Stenting for Lower Limb Atherosclerosis Obliterans: A Machine Learning-Based Study

Frontiers in Cardiovascular Medicine, 2022
BackgroundThe current scoring systems could not predict prognosis after endovascular therapy for peripheral artery disease. Machine learning could make predictions for future events by learning a specific pattern from existing data.
Tianyue Pan, Tianyue Pan, Xiaolang Jiang, Xiaolang Jiang, Hao Liu, Hao Liu, Yifan Liu, Yifan Liu, Weiguo Fu, Weiguo Fu, Zhihui Dong, Zhihui Dong   +11 more
doaj   +1 more source

Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease

Journal of the American College of Cardiology, 2018
BACKGROUND:Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE). There is limited information on the prognosis of patients who experience MALE.OBJECTIVES:Among participants with lower extremity PAD, this study investigated: 1) if ...
Anand, Sonia, Caron, François, Eikelboom, John, Bosch, Jackie, Dyal, Leanne, Aboyans, Victor, Abola, Maria Teresa, Branch, Kelley R.H., Keltai, Katalin, Bhatt, Deepak, Verhamme, Peter, Fox, Keith A.A., Cook-Bruns, Nancy, Lanius, Vivian, Connolly, Stuart, Yusuf, Salim   +15 more
openaire   +2 more sources

Preventive Therapies in Peripheral Arterial Disease

Biomedicines, 2023
Atherosclerosis, while initially deemed a bland proliferative process, is now recognized as a multifactorial-lipoprotein-mediated inflammation-driven pathway.
Aangi J. Shah, Nicholas Pavlatos, Dinesh K. Kalra   +2 more
doaj   +1 more source

Adverse events in British hospitals: preliminary retrospective record review

, 2001
Objectives: To examine the feasibility of detecting adverse events through record review in British hospitals and to make preliminary estimates of the incidence and costs of adverse events.
Neale, G., Vincent, C., C. Vincent, Woloshynowych, M.   +3 more
core   +2 more sources

Artificial Intelligence of Arterial Doppler Waveforms to Predict Major Adverse Outcomes Among Patients Evaluated for Peripheral Artery Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Patients with peripheral artery disease are at increased risk for major adverse cardiac events, major adverse limb events, and all‐cause death.
Robert D. McBane, Dennis H. Murphree, David Liedl, Francisco Lopez‐Jimenez, Itzhak Zachi Attia, Adelaide M. Arruda‐Olson, Christopher G. Scott, Naresh Prodduturi, Steve E. Nowakowski, Thom W. Rooke, Ana I. Casanegra, Waldemar E. Wysokinski, Damon E. Houghton, Haraldur Bjarnason, Paul W. Wennberg   +14 more
doaj   +1 more source

Data on the association between CTRP1 and future major adverse cardiovascular events in patients undergoing coronary angiography. [PDF]

, 2019
This article provides additional data on the association of the new adipokine CTRP1 with the incidence of future major adverse cardiovascular events in a prospective cohort of patients undergoing coronary angiography.
Geiger, Kathrin, Muendlein, Axel, Saely, Christoph, Fraunberger, Peter, Ebner, Janine, Brandtner, Eva Maria, Vonbank, Alexander, Leiherer, Andreas, Drexel, Heinz   +8 more
core   +2 more sources

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. [PDF]

, 2023
Background While the cardiovascular risks of androgen receptor pathway inhibitors have been studied, they were seldom compared directly. This study compares the risks of major adverse cardiovascular events (MACE) between enzalutamide and abiraterone ...
Jeremy Man Ho Hui, Chi Fai Ng, Chi Ho Leung, Yan Hiu Athena Lee, Christopher Tze Wei Tsang, Paul L. Nguyen, Gary Tse, Kyle Hui, Sean McBride, Pias Tang, Kenrick Ng, Jeffrey Shi Kai Chan, Edward Christopher Dee   +12 more
core   +3 more sources

Regular treatment with formoterol for chronic asthma: serious adverse events [PDF]

, 2012
Epidemiological evidence has suggested a link between beta(2)-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe ...
Christopher J Cates, Cates, MJ, Matthew J Cates, Cates, CJ   +3 more
core   +1 more source

Risk factors associated with major adverse cardiac events.

, 2023
Risk factors associated with major adverse cardiac events.
Joon-Young Yoon (17403725), Young-Ok Na (14204628), Sae-Hee Jeong (17403728), Hong-Joon Shin (2967390), Jae-Kyeong Lee (10099045), Yu-Il Kim (798679), Tae-Ok Kim (3183162), Sung-Chul Lim (226845), Yong-Soo Kwon (754013), Bo Gun Kho (10099048)   +9 more
core   +1 more source